Compounded Semaglutide Is Ending — Your Safe, Cheaper Options

If you've been paying $150–$250 a month for compounded semaglutide or compounded tirzepatide, you already know the news stings: that era is ending.

The FDA has been methodically removing compounded GLP-1s from the market, and by mid-2026 most legitimate compounding pharmacies have stopped filling these prescriptions entirely.

Here's the good news: there are now more legitimate, affordable paths to brand-name GLP-1s than at any point in history — some as low as $149 a month without insurance.

Specifically, you'll learn why compounded GLP-1s are being phased out, how to avoid the dangerous gray-market trap, and every real cash-pay and coverage option available as of June 2026.

Why Compounded GLP-1s Are Being Phased Out

The story starts with a shortage.

When Wegovy and Ozempic faced severe supply shortages in 2022 and 2023, the FDA placed semaglutide on its "drug shortage list." That designation opened a legal door: compounding pharmacies are permitted to copy FDA-approved drugs when a documented shortage exists.

Hundreds of compounding pharmacies walked through that door, and millions of patients followed — mostly because the price gap was enormous.

But the shortage eventually resolved. Once the FDA formally removed semaglutide from the shortage list, the legal basis for compounding it largely disappeared. The same story played out for tirzepatide.

Here's the thing:

The FDA's position is not that compounding is always illegal — it's that compounding a drug that is commercially available and not in shortage is generally not permitted. With Wegovy, Zepbound, and now oral options fully back on shelves, that bar is very hard to clear.

Most legitimate 503A and 503B compounding pharmacies have already wound down their GLP-1 programs or plan to in 2026. Prescriptions that were written under the shortage window are expiring, and new ones face serious regulatory headwinds.

The phase-out is not a punishment for patients. It is the system working as designed — compounding was always meant to be a temporary bridge, not a permanent supply channel.

The practical question is not "can I keep getting compounded GLP-1s?" The practical question is: "What is the cheapest legitimate path forward for me?"

That is exactly what the rest of this article answers.

The Gray-Market Trap You Must Avoid

When a cheap supply disappears, a black market fills the void. We are already seeing it.

Searching online for "semaglutide" or "tirzepatide" now surfaces a wave of websites selling "research-grade peptides," "peptide vials," or simply unlabeled injectable powders with no prescriber involved.

Let's be blunt:

These are not pharmaceutical-grade medications. They are unregulated chemicals sold in a legal gray zone — technically labeled "not for human use" to skirt FDA rules, but marketed with obvious wink-and-nod instructions for injection.

The safety picture here is genuinely alarming. Counterfeits are widespread. Independent testing of gray-market "semaglutide" has found products containing the wrong concentration, inactive filler, or substances that are not semaglutide at all. Patients have been hospitalized.

There is also a legal dimension. Importing unapproved drugs, even for personal use, carries real risk. The "research chemical" framing does not protect buyers in most jurisdictions.

The good news — and this is genuinely good news — is that the legitimate options have gotten dramatically cheaper since 2023. You do not need to take this risk anymore.

Let's look at what you actually have.

Your Cheapest Verified Cash-Pay Options Right Now

This is the section most people reading this article need most.

If you were paying compounded prices and you do not have insurance coverage, here is the current landscape of legitimate cash-pay options as of June 2026. All figures should be verified directly with the manufacturer or program, as prices and expiration dates change.

Wegovy Pill (Oral Semaglutide) — From $149/mo

Novo Nordisk launched an oral semaglutide option under the Wegovy brand, approved for weight loss. The self-pay price is $149 per month for the 1.5 mg and 4 mg doses.

The 4 mg pricing is locked at $149 through August 31, 2026, after which it is expected to rise to approximately $199/mo. The 1.5 mg dose holds at $149.

For someone coming off compounded semaglutide injections, this is a meaningful transition: same active molecule, oral format, legitimate manufacturer supply, and a price point that is competitive with what many compounding pharmacies were charging.

Wegovy Injection — $199 for Your First Two Fills

If you prefer the injectable, Novo Nordisk's Wegovy Savings Offer brings the price to $199/mo for the first two fills for new patients. This offer runs through June 30, 2026. After that, the ongoing self-pay price is approximately $349/mo for most doses, or $399/mo for the high-dose (Wegovy HD) option.

Here's what that means for you:

If you have not yet started Wegovy as a new patient and you act before June 30, 2026, you lock in two months at $199. Then you either continue at ~$349 or reassess your options.

Zepbound (Tirzepatide) Vials — From ~$299/mo

Eli Lilly sells Zepbound directly through LillyDirect at self-pay prices starting around $299/mo for lower doses. Higher doses cost more — check the LillyDirect site for current dose-specific pricing.

This is the tirzepatide path for people who were on compounded tirzepatide and want to stay on the same molecule. For more detail on navigating every Zepbound cost option, see our guide on how to afford Zepbound in 2026.

Foundayo (Orforglipron) — The New $149/mo Oral Option

Foundayo, branded orforglipron, is the first oral GLP-1 pill that is a small molecule — meaning it does not require the special timing and fasting requirements of oral semaglutide. It was FDA-approved on April 1, 2026, for weight loss in adults with obesity.

Self-pay starts at $149/mo. With a commercial insurance savings card, it can drop to as low as $25/mo. Medicare-eligible patients in qualifying Part D plans can access it at approximately $50/mo through the Medicare GLP-1 Bridge (more on that below).

This is the newest option on the market and may not yet be widely familiar to prescribers, but it is fully FDA-approved and legitimately manufactured. For a side-by-side comparison of your options, see Foundayo vs Wegovy vs Zepbound: Cost, Coverage and Which to Fight For.

The bottom line: the cheapest legitimate cash-pay options now start at $149/mo. That is within range of what many people were paying for compounded versions — and it comes with the full safety profile of an FDA-approved, manufacturer-produced drug.

How Insurance Coverage Actually Works (and How to Fight For It)

Cash pay is not the only path. If you have commercial insurance and have never pushed for coverage, it may be worth trying before you default to self-pay.

Understanding the system makes the difference between an approval and a denial letter.

What Most Plans Require for a Prior Authorization

Nearly every insurer that covers GLP-1s for weight loss will require prior authorization. The standard criteria look like this:

• A qualifying BMI — typically BMI ≥ 30, OR BMI ≥ 27 with at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
• Documented participation in a reduced-calorie diet and increased physical activity — often 3 to 6 months of documented effort
• Sometimes "step therapy" — you must try and document failure of a less expensive drug before the GLP-1 is approved
• An FDA-approved indication that matches what you are requesting
• Prescriber documentation and chart notes that support every criterion above

Here is where most patients lose:

The denial is often not because you don't qualify — it is because the chart does not clearly document that you qualify. A BMI that was measured six months ago and never re-entered in recent notes, a comorbidity that was mentioned but not formally coded, a lifestyle program that was discussed but not written into the record — these gaps get prescriptions denied.

The Most Common Denial Reasons

• The plan excludes weight-loss drugs as an entire category — this is a benefit design decision, not a clinical one, and it is very common in employer plans
• BMI or comorbidity not documented in the chart at the time of the request
• Step therapy not completed or not documented
• Requesting a diabetes drug (Ozempic, Mounjaro) for weight loss — this is an off-label use and is routinely denied
• Missing lifestyle program documentation
• The drug is not on the plan's formulary because a different GLP-1 is preferred

The Coverage Levers Most People Miss

There are two framing strategies that significantly improve approval odds.

First: Wegovy carries an FDA indication specifically to reduce cardiovascular risk in adults with established cardiovascular disease and obesity or overweight. If you have a prior heart attack, stroke, or documented coronary artery disease, this framing can unlock coverage that a pure "weight loss" request would not.

Second: Semaglutide and tirzepatide are covered far more readily for type 2 diabetes. If you have a diabetes diagnosis, the request should be framed around that indication — using Ozempic or Mounjaro as the diabetes medication, not a weight-loss drug.

If You Get Denied, Here Is the Appeal Ladder

• Internal appeal #1: Submit a letter of medical necessity that ties your documented record to each specific criterion the plan named in its denial
• Peer-to-peer review: Your prescriber speaks directly with the plan's medical director — this step alone reverses a meaningful share of denials
• Internal appeal #2: Submit additional documentation if anything new is available
• External review: An independent review organization examines the case — this is where benefit-exclusion versus medical-necessity disputes often get decided

One important caveat: if your plan has a hard benefit exclusion — meaning it does not cover anti-obesity medications as a category — appeals rarely change the outcome. When you hit that wall, pivot to a cash-pay path or look at whether a different indication (cardiovascular, diabetes) opens coverage. Our full guide on how to appeal a GLP-1 denial walks through each step in detail.

Medicare and Medicaid: What Changed in 2026

Government insurance has historically been the hardest wall to get past for GLP-1 weight-loss coverage. That is starting to change — but only partially.

The Medicare GLP-1 Bridge

Starting July 1, 2026, a limited Medicare demonstration program opens a new path for some Part D members. The cost is approximately $50/mo after the deductible.

The drugs included are Wegovy injection, Wegovy pill, Ozempic, Mounjaro, Zepbound, and Foundayo.

Here is the critical catch:

This is a time-bound demonstration program, not permanent coverage. Not every Part D plan participates. Not every Medicare enrollee qualifies. Standard Medicare still does not cover GLP-1s for weight loss outside of this program — coverage for diabetes or cardiovascular disease remains the reliable Medicare path.

If you are on Medicare and want to explore the Bridge, verify with your specific Part D plan whether it participates before counting on this pricing.

For full details, see our Medicare GLP-1 Bridge guide.

Medicaid Is a State-by-State Question

Medicaid covers GLP-1s for diabetes in nearly every state. Weight-loss coverage is a different story.

As of 2026, 13 states have confirmed coverage for GLP-1s for weight loss. Three states — California, Michigan, and Pennsylvania — are confirmed to be cutting that coverage in 2026.

If you are on Medicaid and relying on GLP-1 coverage for weight loss, check your state's current formulary. The landscape is shifting in both directions. Our Medicaid GLP-1 coverage guide tracks state-by-state status.

How to Pick Your Next Move

Every person's situation is different, but this framework covers most of the common cases.

If You Were on Compounded Semaglutide and Have No Insurance

Your clearest path is the Wegovy pill at $149/mo self-pay, or Foundayo at $149/mo self-pay. Both are oral options that do not require insurance. The Wegovy pill uses the same active molecule you were already taking. Foundayo is a newer molecule with different dosing mechanics — your prescriber can help you decide which is appropriate.

If You Were on Compounded Tirzepatide and Have No Insurance

Zepbound vials through LillyDirect start at approximately $299/mo for lower doses. This is more expensive than compounded tirzepatide was, but it is the legitimate, FDA-approved version. Check our article on the cheapest legitimate way to get Ozempic without insurance for a broader look at how self-pay GLP-1 navigation works in practice.

If You Have Commercial Insurance and Have Never Filed a Prior Authorization

It is worth trying. Work with your prescriber to ensure every criterion is clearly documented in your chart before the PA is submitted. Frame the request around the strongest indication that applies to your medical history — cardiovascular risk reduction, diabetes, or weight loss with documented comorbidities.

If You Are on Medicare

Check whether your Part D plan participates in the GLP-1 Bridge starting July 1, 2026. If it does, the ~$50/mo pricing makes brand-name GLP-1s genuinely accessible. Foundayo may be the most affordable option at that price point. If your plan does not participate, the cash self-pay programs are your next option.

The safety reminder is worth repeating one more time.

GLP-1 medications are real prescription drugs with real risks. Semaglutide, tirzepatide, and orforglipron (Foundayo) all carry a boxed warning for thyroid C-cell tumors and are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Every decision about whether to take a GLP-1, which one, and at what dose belongs with a licensed clinician — not a website, including this one.

Your Next Move

Compounded GLP-1s served a real purpose when drug shortages were acute and brand-name prices were out of reach for most people. That window is closing, but the cost landscape for legitimate options is better than it has ever been.

The $149/mo oral options, the LillyDirect vials, the Medicare Bridge, and a well-executed insurance appeal each represent a real path forward — without the safety risks of gray-market peptides or the regulatory uncertainty of compounding that no longer has a legal foundation.

Which of these paths fits your situation — do you have commercial insurance worth fighting, or is a cash-pay program your fastest route?